NCT01062152 - Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

March 31, 2013

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Ezatiostat Hydrochloride

Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.

DRUG

Lenalidomide (Revlimid®)

10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.

Trial Locations (9)

Columbia University Medical Center, New York

University of Rochester Medical Center, Rochester

Center for Cancer and Blood Disorders, Bethesda

Cleveland Clinic, Cleveland

Loyola University Chicago Cardinal Benardin Cancer Center, Maywood

MDAnderson, Houston

Cancer Care Centers of South Texas, San Antonio

Mayo Clinic, Phoenix

Dana Farber Cancer Institute, Boston